Evoke Pharma, Inc. (NASDAQ: EVOK)*
As of 14 March 2025
Summary
Financial Highlights
Total revenue for 2024: $10.2 million (97% year-over-year increase)
Q4 2024 revenue: $3.3 million (24.6% sequential increase)
Net loss for 2024: $5.4 million ($2.81 per share) vs. $7.8 million in 2023
Cash position: $13.6 million as of December 31, 2024
2025 revenue guidance: approximately $16 million (60% increase over 2024)
Cash runway extended into Q1 2026
Commercial Performance
46% increase in prescribers year-over-year (total: 2,553 prescribers)
72% increase in fill rates year-over-year
22% growth in patient enrollments
Average 6.5 scripts per prescriber, with 65-75 new prescribers added monthly
30% faster speed to therapy for patients
Strategic Developments
Transition to ASPN Pharmacies network significantly improved prescription fulfillment
Expanded pharmacy distribution network with seven additional dispensing pharmacies
Added four field reimbursement managers to improve prior authorization process
Secured two additional Orange Book-listed patents (now six patents extending to 2030)
Launched AI-powered omnichannel marketing campaign focused on switching from oral medications
Clinical Validation
Presented healthcare resource utilization data at ACG showing GIMOTI's superiority over oral metoclopramide
Received Presidential Poster Award at ACG for research on GIMOTI's potential as supportive therapy for GLP-1 users experiencing gastroparesis symptoms
Real-world data demonstrated GIMOTI significantly reduced ER visits and hospitalizations compared to oral metoclopramide
Competitive Landscape
FDA's discontinuation of Domperidone via compassionate use program and Vanda's Complete Response Letter strengthen GIMOTI's market position
GIMOTI remains the only FDA-approved non-oral treatment for gastroparesis
The company expressed confidence in continued growth through expanded pharmacy partnerships, increased provider engagement, leveraging real-world data for payer discussions, and improving prescription fulfillment rates.